Tempus AI, Inc. 8K

Tempus AI, Inc. agreed to acquire Personalis, Inc. in a roughly $1.5 billion primarily stock transaction to integrate Personalis’ MRD cancer monitoring technology into Tempus’ AI‑enabled precision oncology platform, with closing targeted for late 2026 or early 2027 pending approvals.

On July 20, 2026, Tempus AI, Inc. announced that it entered into a definitive agreement to acquire all outstanding shares of Personalis, Inc. that it does not already own for $16.25 per share, implying an enterprise value of approximately $1.5 billion net of its existing stake, in a transaction structured as 100% stock (with Tempus able to elect up to 50% in cash) using a floating exchange ratio of Tempus common stock per Personalis share capped at 0.3356; the deal, approved by both companies’ boards and expected to close in late 2026 or early 2027 subject to Personalis shareholder and regulatory approvals, is intended to combine Personalis’ tumor‑informed minimal residual disease (MRD) technology and NeXT Personal test with Tempus’ large multimodal data assets, AI platform, and commercial scale to expand MRD cancer monitoring, accelerate biomarker discovery, and support growth in the roughly $20 billion MRD market, with Tempus financing any cash portion from cash on hand and credit facilities while citing Personalis’ preliminary Q2 revenue of $22.4 million and 33% quarter‑over‑quarter clinical test volume growth as part of the strategic rationale.

Filing Facts

CIK

1717115

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-308469

Alert Tier

8